Posted by Michael Wonder on 23 Jul 2017
European Commission approves marketing authorisation for Veltassa
21 July 2017 - First launches planned from the end of 2017 or early 2018.
The European Commission has approved patiromer to be marketed as Veltassa in the 28 EU countries for the treatment of elevated serum potassium levels (hyperkalaemia) in adult patients. The approval is also accepted in Norway, Iceland and Liechtenstein.
Developed by Relypsa, Veltassa was approved by the US FDA for the treatment of hyperkalaemia in the US in October 2015 and has been available to patients in the US since December 2015. Marketing authorisation applications for Veltassa have been submitted and are under review in Switzerland and Australia, and are planned in other markets worldwide.
